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TNF alpha in the two treatment arms and further study is needed 
to determine the significance of this observation. 
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ANALYSIS OF CD4+CD25 ÷ T REGULATORY CELL SURVIVAL AND 
FUNCTION FOLLOWING IN VITRO AND IN VIVO IRRADIATION 
Zi71~.Me~'~a~, Z.F.; Baez, a7.; Rodeos, M.; ~la~n~ole~ti, ~.;  Levy, R.R 
Microbiology m~d Immmmlogh U~ive'~sit3, of 3/Iiami &'hool of Medid~te, 
Miami, FL. 
Manipulating the host regulatory T cell compartment may be 
useful in BMT strategies for successful engraftment and anti- 
tumor responses. In order to investigate he effect of conditioning 
regimens on host CD4+CD25 + T regulatory cell function prior to 
BMT, highly purified populations of Tregs were produced from 
several mouse strains and exposed to varying levels of gamma irra- 
diation ex vivo. Following treatment, Tregs were co-cultured with 
CD4+CD25 rcsponders, accessory cells, and anti-CD3 mAb. At 
doses as low as 3.0 Gy, Tregs exhibited iminished capacity to 
regulate CD4+ T cell proliferation i~ vit*v. To assess the effect of 
the radiation on Treg survival, purified populations were exposed 
to doses front 3.0Gy to 9.0Gy and assessed by Annexin V staining. 
After 24 hrs., >90% of the Tregs were positive regardless of dose. 
Co-culture with accessory cells and stinmlation with anti-CD3 
during this time period could not rescue these cells from death. 
To examine cell survival following i*z vivo irradiation, splenic 
CD4+CD25 + cells were purified from mice immediately following 
3.0 or 9.0Gy TBI and cultured for 24 hrs. Annexin V staining was 
equivalently as high as in Tregs irradiated ex vivo. Further analysis 
following ex vivo irradiation indicated that apoptotic ells were 
evident between 4 and 8 hours post-exposure. Since >90% of 
Tregs exposed to a dose of 3.0Gy are undergoing apoptosis by 24 
hrs, and these cells did not lose the entirety of their regulato W 
function, four hours after 3.0 Gy, irradiated Tregs were co-cul- 
tured with anti-CD3 and CD25- responding cells to determine the 
kinetics of function post-irradiation. These Tregs failed to exhibit 
any regulatory activity. It may be notable that 24 hrs following 
busulfan treatment (30mg/kg) of B6 mice, CD4+CD25 + Treg ceils 
maintained their ability to regulate CD4 T cell proliferation, in 
total, these observations suggest that immediately following doses 
of ->3.0Gy Treg survival and function appear to be compromised. 
Additionally, alternative conditioning regimens may differentially 
affect he functional capacity of host Treg cells following BMT. 
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THE INFLUENCE OF THE GRAFT MONOCYTES IN THE OUTCOME OF 
ALLOGENEIC BONE MARROW TRANSPLANTATION 
Pe1~teaclo Ara~ha, F.J.; P'igot-ito, A.C.; De Soztza, C.A.; Bo~'ba 
Oliveira, G.; Brito Eicl, K.A.; Zzdli, R.; Lo~:aml-Met~e, L Bm~e Mar- 
7"ow Tra*zsp/a~m~tio*z, State Ut~iz,eJ'si U of Campit~as, Campmas, Sao 
Pazllo, B*'azil. 
Francisco J P Aranha, Afonso C Vigorito, Carmino A De Sousa, 
Gislaine B Oliveira, Katia A Eid, Roberto Zulli, Irene Lorand- 
Metze Bone Marrow Transplantation Unit State University of 
Campinas, SP/Brazil The influence of graft monocytes on GVHD 
has not yet been established in clinical trials.V~te valuated the 
influence of bone marrow graft monocytes aiming, primarily, to
analyse the correlation with aGVHD and cGVHD, and secondar- 
ily with engra~nent and survival. Eligibility criteria age <60 years; 
patients with primary malignant or non-malignant hematological 
disease receiving BM from an HLA-identical sibling. We analyzed 
83 patients. Conditioning was mainly BuCy2 and GVHD prophy- 
laxis CSA-MTX. The median day to reach peripheral leukocytes _> 
0.5x109/1 and platelet count >20x109/1 was 20 (I 1-34) and 18.5 
(10-60) respectively. In univariate analysis, any parameter was cor- 
related with a faster engrafinent. The frequency of a-GV-HD, 
grades 2-4 was 12/83 (i4.5%). In univariate analysis, TNC 
>2.31x108/Kg and CD14+ cells >4.78x106/Kg were correlated 
significantly with lower rates of a-GVHD (p=0.04, p=0.02, respec- 
tively). Furthermore, patients >27 years old and donor gender 
mismatch ad higher rates of aGVHD (p=0.03 and p=0.04, 
respectively). In a nmltivariate analysis, both TNC and age main- 
tain significance for lower risk of a GVHD. The probability was 
3.2% when age < 27 years and TNC infused _> 2.?1 X 108/Kg. A 
higher risk of a-GVHD was found (51.5%) when age > 27 years 
and TNC infused < 2.31 X 108/Kg (P<0.001).The number of 
CD14+ cells showed a correlation with TNC. This interaction 
might be the cause for the loss of significance for monocytes in 
the multivariate analysis. Clinical c GVHD of all grades devel- 
oped in 31/77 (40%) available patients. It was extensive in 20 cases 
and limited in 11 cases. In univariate analyses there was a correla- 
tion between previous a-GVHD and a higher risk of c-GVHD 
(p<0.001). CD14+ cells did not influence c-GVHD. The estimate 
of 6-year overall survival (OS) was 66% (95% CI: 55%-79%). In 
univariate analyses, the absence of a GVHD was correlated with a 
higher survival (p<0.001). Furthermore, there was a trend for a 
better survival in patients receiving more CD34+ cells (p=0.06). 
The CD14 cells had no impact on overall survival. These prelimi- 
nary data suggest that CD14+ cells may have a protective ffect in 
allogeneic BMT. 
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TNF TYPE II RECEPTOR GENOTYPE AFFECTS SOLUBLE RECEPTOR 
LEVELS IN NORMAL SUBJECTS AND ASSOCIATES WITH CHRONIC 
GVHD SEVERITY 
Stark, G. l; DickitlsoJ?, A.M. ~; ffaclesoJ~, G.H.e; Taylor, P.R. "-; Middle- 
to~, P.G. I 1. U'nive~-sity ofNewcastle, Newcastle Hpo~ Tyze, Ul~ited 
KtJagdom; 2. Royal f'tcto*'ia llz/;JwlaJty , Newamle elpo,z Ty,le, U'Mted 
Ki~gdom. 
A single nucleotide polymorphism in the TNF type II recep- 
tor(TNFRII) gene, at codon 196, results in the substitution f 
arginine (R allele) for methionine (M allele). The R allele is 
reported to associate with susceptibility to autoimmune disease 
and donor R allele carriage correlates with acute graft-versus-host 
disease (GVHD) severity after MUD BMT. To investigate the 
functional impact of this polymorphisln, 81 volunteer blood 
donors were genotyped by PCR and SSCP analysis and soluble 
TNFRII (sTNFRII) levels were measured by ELISA. Mean (+/- 
SEM) plasma sTNFRII levels were 1225+/-26 and I063+/-65 for 
individuals caruing at least 1 M allele (M+) and RR homozygotes 
respectively (p=0.02). We examined the impact of this polymor- 
phism on acute and chronic GVHD incidence/severity after non- 
T ceil-depleted sibling BMT. TNFRII 196 M/R genotype was 
determined amongst 106 transplant recipients, 106 donors and 
131 control subjects. R allele frequency amongst recipients, 
donors and controls was 0.28. In univariate analysis there was a 
trend towards increased acute GVHD incidence [odds ratio (OR) 
2.9] amongst R+ recipients (p=0.1). In nmltivariate analysis by 
logistic regression, correcting for established clinical and genetic 
GVHD risk factors, the impact of recipient TNFRII  R+ status 
was reduced (p=0.13). In univariate analysis, donor RR homozy- 
gosity associated with a trend to increased cGVHD incidence (OR 
4.6; p=0.1) and an increased risk of extensive cGVHD (OR 8.5; 
p=0.01). In nmltivariate analysis donor RR homozygosity associat- 
ed with an increased risk of extensive cGVHD (relative risk 11.3; 
p=0.02) but not cGVHD incidence per se. Since sTNFRIIs can 
act as TNF  antagonists, the association between donor RR 
homozygosity and cGVHD may reflect reduced circulating sTN- 
FRII. The role for pharmacological interventions, particularly the 
use of recombinant sTNFRII (Etanercept) requires further inves- 
tigation, but may be influenced by genotype. 
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RAPID ENGRAFTMENT IS ASSOCIATED WITH AN INCREASED INCI- 
DENCE OF GRAFT VS HOST DISEASE (GVHD) IN CHILDREN FOLLOW- 
ING REDUCED-INTENSITY HEMATOPOIETIC STEM CELL TRANSPLAN- 
TATION (RI-HSCT) 
B~wck~le~; L.1; D'lm1"st, R?, K_letzel, ~[.2 i. Golismm Ch//ch'e77 ;" Hos'pi- 
tnl, UJdversitv of Roc,~este1" Medical Celzter, Rochestel; NY," 2. C,~ttctlw~s 
3/iemo~'ial Hospital, Nol-tbwestelw Utlivevsity, Chicago, IL. 
We conducted a retrospective chart review of I9 children who 
had undergone RI-HSCT at Childrens Memorial Hospital over 
B B & 2PI T 99 
